^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
NovoFocus™ PARPi CDx

Company:
Novogene
Type:
Laboratory Developed Test
Related tests:

Details

Evidence
News
NovoFocus™ PARPi CDx 1.0 is a next-generation sequencing (NGS)-based companion diagnostic (CDx) assay for poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) therapy in ovarian and breast cancers, NovoFocus™ PARPi CDx 1.0 interrogates 45 genes. It can detect genomic abnormalities (SNV, InDel, CNV and Fusion) and homologous recombination deficiency (HRD). Besides, it provides targeted therapy options and related hereditary cancer risk assessment.
Cancer:
Colon Cancer, HER2 Negative Breast Cancer, Ovarian Cancer, Triple Negative Breast Cancer
Gene:
APC (APC Regulator Of WNT Signaling Pathway), AR (Androgen receptor), ATM (ATM serine/threonine kinase), ATR (Ataxia telangiectasia and Rad3-related protein), BARD1 (BRCA1 Associated RING Domain 1), BRCA1 (Breast cancer 1, early onset)
See More ...
Method:
Next-Generation Sequencing (NGS)